Literature DB >> 19247370

Towards an understanding of the adjuvant action of aluminium.

Philippa Marrack1, Amy S McKee, Michael W Munks.   

Abstract

The efficacy of vaccines depends on the presence of an adjuvant in conjunction with the antigen. Of these adjuvants, the ones that contain aluminium, which were first discovered empirically in 1926, are currently the most widely used. However, a detailed understanding of their mechanism of action has only started to be revealed. In this Timeline article, we briefly describe the initial discovery of aluminium adjuvants and discuss historically important advances. We also summarize recent progress in the field and discuss their implications and the remaining questions on how these adjuvants work.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19247370      PMCID: PMC3147301          DOI: 10.1038/nri2510

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  54 in total

1.  Notes on the Production of Immunity to Diphtheria Toxin.

Authors:  A T Glenny; H J Südmersen
Journal:  J Hyg (Lond)       Date:  1921-10

2.  A mechanism for the initiation of allergen-induced T helper type 2 responses.

Authors:  Caroline L Sokol; Gregory M Barton; Andrew G Farr; Ruslan Medzhitov
Journal:  Nat Immunol       Date:  2008-03       Impact factor: 25.606

3.  Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3.

Authors:  Hanfen Li; Stephen B Willingham; Jenny P-Y Ting; Fabio Re
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

4.  Activation of dendritic cells and induction of CD4(+) T cell differentiation by aluminum-containing adjuvants.

Authors:  Anna Sokolovska; Stanley L Hem; Harm HogenEsch
Journal:  Vaccine       Date:  2007-04-19       Impact factor: 3.641

5.  The Common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism.

Authors:  M Ulanova; A Tarkowski; M Hahn-Zoric; L A Hanson
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

6.  The Nlrp3 inflammasome is critical for aluminium hydroxide-mediated IL-1beta secretion but dispensable for adjuvant activity.

Authors:  Luigi Franchi; Gabriel Núñez
Journal:  Eur J Immunol       Date:  2008-08       Impact factor: 5.532

Review 7.  Proteases in parasitic diseases.

Authors:  James H McKerrow; Conor Caffrey; Ben Kelly; P'ng Loke; Mohammed Sajid
Journal:  Annu Rev Pathol       Date:  2006       Impact factor: 23.472

8.  Molecular identification of a danger signal that alerts the immune system to dying cells.

Authors:  Yan Shi; James E Evans; Kenneth L Rock
Journal:  Nature       Date:  2003-09-07       Impact factor: 49.962

Review 9.  Interleukin-18: recent advances.

Authors:  Pavan Reddy
Journal:  Curr Opin Hematol       Date:  2004-11       Impact factor: 3.284

10.  Studies on antibody production. III. The alum granuloma.

Authors:  R G WHITE; A H COONS; J M CONNOLLY
Journal:  J Exp Med       Date:  1955-07-01       Impact factor: 14.307

View more
  266 in total

1.  Vaccine adjuvants aluminum and monophosphoryl lipid A provide distinct signals to generate protective cytotoxic memory CD8 T cells.

Authors:  Megan K L MacLeod; Amy S McKee; Alexandria David; Jieru Wang; Robert Mason; John W Kappler; Philippa Marrack
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-25       Impact factor: 11.205

2.  Reorienting our view of particle-based adjuvants for subunit vaccines.

Authors:  Steven R Little
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-17       Impact factor: 11.205

Review 3.  Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination.

Authors:  Christophe J Desmet; Ken J Ishii
Journal:  Nat Rev Immunol       Date:  2012-06-22       Impact factor: 53.106

Review 4.  Regulation of CD4 T-cell receptor diversity by vaccine adjuvants.

Authors:  Christina K Baumgartner; Laurent P Malherbe
Journal:  Immunology       Date:  2010-03-17       Impact factor: 7.397

Review 5.  Therapeutic cancer vaccines: are we there yet?

Authors:  Christopher A Klebanoff; Nicolas Acquavella; Zhiya Yu; Nicholas P Restifo
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

Review 6.  Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens.

Authors:  Douglas S Watson; Aaron N Endsley; Leaf Huang
Journal:  Vaccine       Date:  2012-02-02       Impact factor: 3.641

Review 7.  Eosinophils: important players in humoral immunity.

Authors:  C Berek
Journal:  Clin Exp Immunol       Date:  2015-09-28       Impact factor: 4.330

Review 8.  ASIA syndrome, calcinosis cutis and chronic kidney disease following silicone injections. A case-based review.

Authors:  Giuseppe Barilaro; Claudia Spaziani Testa; Antonella Cacciani; Giuseppe Donato; Mira Dimko; Amalia Mariotti
Journal:  Immunol Res       Date:  2016-12       Impact factor: 2.829

9.  Evaluation of the efficacy of a novel porcine circovirus type 2 synthetic peptide vaccine.

Authors:  Jiwoon Jeong; Changhoon Park; Seeun Kim; Su-Jin Park; Ikjae Kang; Kee Hwan Park; Chanhee Chae
Journal:  Can J Vet Res       Date:  2018-04       Impact factor: 1.310

10.  Evaluating the efficacy of rBmHATαc as a multivalent vaccine against lymphatic filariasis in experimental animals and optimizing the adjuvant formulation.

Authors:  Gajalakshmi Dakshinamoorthy; Ramaswamy Kalyanasundaram
Journal:  Vaccine       Date:  2013-11-06       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.